NASDAQ:EXAI

Exscientia (EXAI) Stock Forecast, Price & News

$5.17

+0.28 (+5.73%)

(As of 09/22/2023 ET)

Compare

Today's Range: $4.88
▼
$5.27
50-Day Range: $4.53
▼
$8.90
52-Week Range: $4.09
▼
$11.52

Volume: 709,184 shs
Average Volume: 979,856 shs
Market Capitalization: $625.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.00

Exscientia MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 151.5% Upside
$13.00 Price Target
Short Interest: Bearish
1.95% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.49
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.32) to ($1.63) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

759th out of 963 stocks

Biological Products, Except Diagnostic Industry

120th out of 158 stocks

3.3

Analyst's Opinion

Consensus Rating
Exscientia has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.00, Exscientia has a forecasted upside of 151.5% from its current price of $5.17.
Amount of Analyst Coverage
Exscientia has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
1.95% of the float of Exscientia has been sold short.
Short Interest Ratio / Days to Cover
Exscientia has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in Exscientia has recently increased by 13.43%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Exscientia does not currently pay a dividend.
Dividend Growth
Exscientia does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EXAI.

2.5

News and Social Media Coverage

News Sentiment
Exscientia has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Exscientia this week, compared to 1 article on an average week.
Search Interest
17 people have searched for EXAI on MarketBeat in the last 30 days. This is an increase of 89% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exscientia insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.40% of the stock of Exscientia is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
42.68% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Exscientia are expected to decrease in the coming year, from ($1.32) to ($1.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exscientia is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exscientia is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Exscientia has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Exscientia (NASDAQ:EXAI) Stock

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. It also focuses on discovery and development of small molecule drug candidates. The company's platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

EXAI Price History

30 days | 90 days | 365 days | Advanced Chart

EXAI Stock News Headlines

September 24, 2023 | americanbankingnews.com

Exscientia (NASDAQ:EXAI) Sees Unusually-High Trading Volume

September 21, 2023 | markets.businessinsider.com

FedEx, Splunk, FactSet Research And Other Big Stocks Moving Higher On Thursday

September 24, 2023 | Chaikin Analytics (Ad)

Get Your Cash Out of U.S. Banks Immediately

Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.

September 21, 2023 | finance.yahoo.com

Down -33.28% in 4 Weeks, Here's Why Exscientia PLC Sponsored ADR (EXAI) Looks Ripe for a Turnaround

September 20, 2023 | thestreet.com

Exscientia Plc

September 20, 2023 | markets.businessinsider.com

Exscientia Shares Surge On AI Collaboration: The Details

September 20, 2023 | seekingalpha.com

Exscientia: Merck Deal Further Cements Industry Positioning, Reiterate Buy

September 20, 2023 | marketwatch.com

Exscientia Shares Rally Premarket on Lucrative Merck Deal >EXAI

September 24, 2023 | Chaikin Analytics (Ad)

Get Your Cash Out of U.S. Banks Immediately

Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.

September 20, 2023 | finance.yahoo.com

Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany

August 31, 2023 | finance.yahoo.com

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

August 12, 2023 | finance.yahoo.com

Exscientia plc (NASDAQ:EXAI) Analysts Just Trimmed Their Revenue Forecasts By 25%

August 11, 2023 | markets.businessinsider.com

Exscientia Plc (EXAI) Receives a Buy from Barclays

August 10, 2023 | finance.yahoo.com

Exscientia Business Update for Second Quarter and First Half of 2023

August 3, 2023 | finance.yahoo.com

Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023

August 2, 2023 | theglobeandmail.com

Instrument Name Exscientia Ltd ADR Instrument Symbol (EXAI-Q)

August 1, 2023 | msn.com

Exscientia Is Worth The AI-Driven Speculation

July 21, 2023 | finance.yahoo.com

News Flash: Analysts Just Made A Meaningful Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts

July 20, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Exscientia

July 18, 2023 | finance.yahoo.com

Exscientia Initiates Prospective Observational Study in Ovarian Cancer

July 13, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Technology Companies: Endava (DAVA) and Exscientia Plc (EXAI)

July 12, 2023 | finance.yahoo.com

Why Shares of Exscientia Jumped on Wednesday

July 10, 2023 | benzinga.com

GT Apeiron Announces Enrollment of First Patient in Phase 1/2 "ELUCIDATE" Clinical Trial of CDK7 Inhibitor, GTAEXS617, in Advanced Solid Tumors

July 10, 2023 | finance.yahoo.com

First Patient Enrolled in Phase 1/2 "ELUCIDATE" Trial Assessing GTAEXS617 in Advanced Solid Tumours

June 29, 2023 | finance.yahoo.com

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

June 29, 2023 | finance.yahoo.com

Exscientia Announces Expansion of its Technology Leadership Team

June 28, 2023 | msn.com

Cullinan Oncology: Playing 'Moneyball' In The Drug Development Sector

See More Headlines

Receive EXAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter.

EXAI Company Calendar

Last Earnings: 8/10/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EXAI
CUSIP: N/A
CIK: 1865408
Web: www.exscientia.ai
Phone: 44-0-18-6581-8941
Fax: N/A
Employees: 481
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.00
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +151.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-146,850,000.00
Net Margins: -685.82%
Pretax Margin: -810.00%
Return on Equity: -31.67%
Return on Assets: -23.59%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 6.88
Quick Ratio: 6.88

Sales & Book Value

Annual Sales: $32.90 million
Price / Sales: 19.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.82 per share
Price / Book: 1.07

Miscellaneous

Outstanding Shares: 120,890,000
Free Float: 101,062,000
Market Cap: $625.00 million
Optionable: Not Optionable
Beta: 0.55

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Prof. Andrew L. Hopkins DPHIL (Age 50)
FMEDSCI, FRSE FRSC, Founder, CEO & Exec. Director
Comp: $682.34k

Mr. Ben R. Taylor (Age 46)
CFO, Chief Strategy Officer & Exec. Director
Comp: $478.29k

Dr. David Hallett Ph.D. (Age 52)
Chief Scientific Officer

Dr. Garry Pairaudeau Ph.D. (Age 57)
Advisor

Dr. Michael Krams M.D. (Age 62)
Chief Quantitative Medicine Officer

Ms. Eileen Jennings-Brown
Chief Information Officer

Mr. Dan Ireland
VP of Legal & Company Sec.

Ms. Caroline Rowland
Chief People Officer

Mr. Richard Law
Chief Bus. Officer

Prof. Charlotte Deane M.B.E.
Ph.D., Chief AI Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

EXAI Stock - Frequently Asked Questions

Should I buy or sell Exscientia stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAI shares.
View EXAI analyst ratings or view top-rated stocks.
What is Exscientia's stock price forecast for 2023?: 3 brokerages have issued 1-year target prices for Exscientia's stock. Their EXAI share price forecasts range from $12.00 to $14.00. On average, they anticipate the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 151.5% from the stock's current price.
View analysts price targets for EXAI or view top-rated stocks among Wall Street analysts.
How have EXAI shares performed in 2023?: Exscientia's stock was trading at $5.33 at the start of the year. Since then, EXAI shares have decreased by 3.0% and is now trading at $5.17.
View the best growth stocks for 2023 here.
Are investors shorting Exscientia?: Exscientia saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,280,000 shares, an increase of 13.4% from the August 15th total of 2,010,000 shares. Based on an average daily volume of 339,000 shares, the days-to-cover ratio is currently 6.7 days. Currently, 2.0% of the shares of the stock are sold short.
View Exscientia's Short Interest.
When is Exscientia's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our EXAI earnings forecast.
How were Exscientia's earnings last quarter?: Exscientia plc (NASDAQ:EXAI) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.04. The firm had revenue of $3.80 million for the quarter, compared to the consensus estimate of $16.27 million. Exscientia had a negative net margin of 685.82% and a negative trailing twelve-month return on equity of 31.67%.
What ETFs hold Exscientia's stock?: ETFs with the largest weight of Exscientia (NASDAQ:EXAI) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Exscientia IPO?: (EXAI) raised $291 million in an initial public offering on Friday, October 1st 2021. The company issued 13,850,000 shares at $20.00-$22.00 per share.
What is Exscientia's stock symbol?: Exscientia trades on the NASDAQ under the ticker symbol "EXAI."
Who are Exscientia's major shareholders?: Exscientia's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (4.20%), Platinum Investment Management Ltd. (3.30%), Pivotal bioVenture Partners Investment Advisor LLC (0.64%), Woodline Partners LP (0.63%), BlackRock Inc. (0.57%) and Point72 Asset Management L.P. (0.48%).
How do I buy shares of Exscientia?: Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Exscientia's stock price today?: One share of EXAI stock can currently be purchased for approximately $5.17.
How much money does Exscientia make?: Exscientia (NASDAQ:EXAI) has a market capitalization of $625.00 million and generates $32.90 million in revenue each year. The company earns $-146,850,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.
How many employees does Exscientia have?: The company employs 481 workers across the globe.
How can I contact Exscientia?: The official website for the company is www.exscientia.ai. The company can be reached via phone at 44-0-18-6581-8941 or via email at investors@exscientia.ai.

This page (NASDAQ:EXAI) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial